PLASMANATE Side Effects

6032178-0 | Non-cardiogenic Pulmonary Oedema, Transfusion-related Acute Lung Injury
on Dec 17, 2008 Male patient from JAPAN , 72 years of age, was diagnosed with operative haemorrhage and was treated with Plasmanate (View Usage). Patient experienced the following unwanted or unexpected effects: non-cardiogenic pulmonary oedema, transfusion-related acute lung injury. Plasmanate dosage: 750 Ml; Iv. During the same period patient was treated with RED BLOOD CELLS (12 Units; Iv) (View Red Blood Cells Review and Red Blood Cells Label ), WHOLE BLOOD (800 Ml; Iv) (View Whole Blood Review and Whole Blood Label ), MANNITOL (; Iv) (View Mannitol Review and Mannitol Label ).

5794408-X | Hepatitis C Antibody Positive, Shock Haemorrhagic
Patient was taking Plasmanate (View Usage). Patient had the following side effects: hepatitis c antibody positive, shock haemorrhagic on Jun 05, 2008 from JAPAN Additional patient health information: Female patient , 76 years of age, weighting 102.5 lb, was diagnosed with shock haemorrhagic, anaemia and. Plasmanate dosage: 250 Ml; 1x; Iv. During the same period patient was treated with RED CELLS MAP (RED BLOOD CELLS, CONCENTRATED) (400 Ml; Iv) (View Red Cells Map (red Blood Cells, Concentrated) Review and Red Cells Map (red Blood Cells, Concentrated) Label ).

5794407-8 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Hepatic Function Abnormal, Hepatitis B E Antigen Positive, Hepatitis B Surface Antigen Positive
Adverse event was reported on Jun 05, 2008 by a Male patient taking Plasmanate (View Usage) (Dosage: 250 Ml; Iv) was diagnosed with hypoalbuminaemia, sepsis (What is sepsis?) and. Location: JAPAN , 63 years of age, weighting 136.7 lb, After Plasmanate was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, hepatic function abnormal, hepatitis b e antigen positive, hepatitis b surface antigen positive. During the same period patient was treated with ALBUMIN (HUMAN) (100 Ml; Iv) (View Albumin (human) Review and Albumin (human) Label ), VENOGLOBULIN I (500 Mg;) (View Venoglobulin-i Review and Venoglobulin-i Label ). Patient was hospitalized.

5794404-2 | Anti-hbc Igg Antibody Positive, Anti-hbs Antibody Positive, Hepatitis B Antibody Positive, Hepatitis B Surface Antigen Positive
on Jun 09, 2008 Female patient from JAPAN , 40 years of age, weighting 165.3 lb, was diagnosed with volume blood decreased, operative haemorrhage and was treated with Plasmanate (View Usage). Patient experienced the following unwanted or unexpected effects: anti-hbc igg antibody positive, anti-hbs antibody positive, hepatitis b antibody positive, hepatitis b surface antigen positive. Plasmanate dosage: 250 Ml; Iv. During the same period patient was treated with RED BLOOD CELLS (8 E;) (View Red Blood Cells Review and Red Blood Cells Label ), TRANSAMIN (View Transamin Review and Transamin Label ), ADONA /04876801/ (View Adona /04876801/ Review and Adona /04876801/ Label ), OTSUKA CEZ MC (View Otsuka Cez Mc Review and Otsuka Cez Mc Label ), PANTOL /00223901/ (View Pantol /00223901/ Review and Pantol /00223901/ Label ), GAMOFA (View Gamofa Review and Gamofa Label ), TACHOCOMB /01002401/ (View Tachocomb /01002401/ Review and Tachocomb /01002401/ Label ).


5781711-2 | Transfusion-related Acute Lung Injury
on May 28, 2008 Male patient from JAPAN , 72 years of age, was diagnosed with operative haemorrhage and was treated with Plasmanate (View Usage). Patient had the following side effects: transfusion-related acute lung injury. Plasmanate dosage: 750 Ml; Iv. During the same period patient was treated with RED BLOOD CELLS (12 Units; Iv) (View Red Blood Cells Review and Red Blood Cells Label ), WHOLE BLOOD (800 Ml; Iv) (View Whole Blood Review and Whole Blood Label ), MANNITOL (Iv) (View Mannitol Review and Mannitol Label ).

5117017-4 | Anaphylactic Shock
Patient was taking Plasmanate (View Usage). After Plasmanate was administered, patient had the following side effects: anaphylactic shock on Sep 15, 2006 from JAPAN Additional patient health information: Male patient , 69 years of age, weighting 103.6 lb, was diagnosed with volume blood increased and. Plasmanate dosage: 400 Ml, Intravenous Drip. During the same period patient was treated with SEVOFLURANE (View Sevoflurane Review and Sevoflurane Label ), CARBOCAIN (View Carbocain Review and Carbocain Label ), MUSCULAX (View Musculax Review and Musculax Label ).

5103966-X | Anaphylactic Reaction
Adverse event was reported on Aug 29, 2006 by a Male patient taking Plasmanate (View Usage) (Dosage: 400 Ml, Intravenous Drip) was diagnosed with volume blood increased and. Location: JAPAN , 69 years of age, weighting 103.6 lb, Patient experienced the following unwanted or unexpected effects: anaphylactic reaction.

5069902-X | Anaphylactic Reaction
on Jul 12, 2006 Male patient from JAPAN , 69 years of age, was diagnosed with volume blood and was treated with Plasmanate (View Usage). Patient had the following side effects: anaphylactic reaction. Plasmanate dosage: Intravenous Drip.

4838130-2 | Anaphylactic Reaction
on Aug 08, 2005 Female patient from JAPAN , 57 years of age, was diagnosed with operative haemorrhage and was treated with Plasmanate (View Usage). After Plasmanate was administered, patient had the following side effects: anaphylactic reaction. Plasmanate dosage: 1500 Ml, Total Daily. During the same period patient was treated with RED BLOOD CELLS (Intravenous) (View Red Blood Cells Review and Red Blood Cells Label ), PROPOFOL (View Propofol Review and Propofol Label ), FENTANYL (View Fentanyl Review and Fentanyl Label ), KETAMINE HCL (View Ketamine Hcl Review and Ketamine Hcl Label ), CHOLINE DERIVATIVES AND PREPARATIONS (View Choline Derivatives And Preparations Review and Choline Derivatives And Preparations Label ), VECURONIUM BROMIDE (View Vecuronium Bromide Review and Vecuronium Bromide Label ). Patient was hospitalized.

4708343-9 | Anaphylactic Reaction, Erythema, Tryptase Increased
Patient was taking Plasmanate (View Usage). Patient experienced the following unwanted or unexpected effects: anaphylactic reaction, erythema, tryptase increased on Jun 16, 2005 from Additional patient health information: Female patient , 57 years of age, was diagnosed with operative haemorrhage and. Plasmanate dosage: 1500 Ml, Total Daily. During the same period patient was treated with RED BLOOD CELLS (Intravenous) (View Red Blood Cells Review and Red Blood Cells Label ), PROPOFOL (View Propofol Review and Propofol Label ), FENTANYL (View Fentanyl Review and Fentanyl Label ), KETAMINE HCL (View Ketamine Hcl Review and Ketamine Hcl Label ), CHOLINE DERIVATIVES AND PREPARATIONS (View Choline Derivatives And Preparations Review and Choline Derivatives And Preparations Label ), VECURONIUM BROMIDE (View Vecuronium Bromide Review and Vecuronium Bromide Label ). Patient was hospitalized.

4708343-9 | Anaphylactic Reaction, Erythema, Tryptase Increased
Adverse event was reported on Jun 16, 2005 by a Female patient taking Plasmanate (View Usage) (Dosage: 1500 Ml, Total Daily) was diagnosed with operative haemorrhage and. Location: JAPAN , 57 years of age, Patient had the following side effects: anaphylactic reaction, erythema, tryptase increased. During the same period patient was treated with RED BLOOD CELLS (Intravenous) (View Red Blood Cells Review and Red Blood Cells Label ), PROPOFOL (View Propofol Review and Propofol Label ), FENTANYL (View Fentanyl Review and Fentanyl Label ), KETAMINE HCL (View Ketamine Hcl Review and Ketamine Hcl Label ), CHOLINE DERIVATIVES AND PREPARATIONS (View Choline Derivatives And Preparations Review and Choline Derivatives And Preparations Label ), VECURONIUM BROMIDE (View Vecuronium Bromide Review and Vecuronium Bromide Label ). Patient was hospitalized.

4577733-X | Central Pontine Myelinolysis, Marchiafava-bignami Disease
on Jan 16, 2005 Male patient from , 50 years of age, was treated with Plasmanate (View Usage). After Plasmanate was administered, patient had the following side effects: central pontine myelinolysis, marchiafava-bignami disease. Plasmanate dosage: . During the same period patient was treated with PLASMA PROTEIN FRACTION (HUMAN) (View Plasma Protein Fraction (human) Review and Plasma Protein Fraction (human) Label ).

4565297-6 | Anaemia, Anaphylactic Shock, Antibody Test Positive, Coagulopathy, Coronary Artery Occlusion, Haptoglobin Decreased, Histamine Level Increased, Hypoalbuminaemia, Ventricular Fibrillation
on Jan 10, 2005 Male patient from , 71 years of age, weighting 99.21 lb, was treated with Plasmanate (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, anaphylactic shock, antibody test positive, coagulopathy, coronary artery occlusion, haptoglobin decreased, histamine level increased, hypoalbuminaemia, ventricular fibrillation. Plasmanate dosage: . During the same period patient was treated with FRESH FROZEN PLASMA (View Fresh Frozen Plasma Review and Fresh Frozen Plasma Label ), ANESTHESIA (View Anesthesia Review and Anesthesia Label ), PROPOFOL (View Propofol Review and Propofol Label ), VECURONIUM (View Vecuronium Review and Vecuronium Label ). Patient was hospitalized.

4558370-X | Anaphylactic Shock, Atrioventricular Block, Bradycardia, Cardiac Arrest, Erythema
Patient was taking Plasmanate (View Usage). Patient had the following side effects: anaphylactic shock, atrioventricular block, bradycardia, cardiac arrest (What is cardiac arrest?), erythema on Jan 06, 2005 from Additional patient health information: Male patient , 66 years of age, weighting 136.7 lb, was diagnosed with fluid replacement and. Plasmanate dosage: 1000 Ml, Total Daily, Intravenous Drip. During the same period patient was treated with KAKODIN (View Kakodin Review and Kakodin Label ), MAP (View Map Review and Map Label ), HABEKACIN (View Habekacin Review and Habekacin Label ), UNASYN (View Unasyn Review and Unasyn Label ).